文献速递妇科生殖医学

双侧浆液性交界性卵巢肿瘤保留生育治疗后的肿瘤生育结局:大型回顾性研究

Oncofertility outcomes after fertility-sparing treatment of bilateral serous borderline ovarian tumors: results of a large retrospective study.
PubMed 文献 · Hum Reprod · 2020-01-01

49例尝试妊娠者中23例(47%)获得27次妊娠、19例活产。双侧囊肿剥除在技术可行时可作为保留生育的选择。

要点

  • 双侧卵巢囊肿剥除术在双侧SBOT中技术可行,肿瘤结局可接受且妊娠率尚可。
  • 术前CA-125>300 U/mL、保留生育手术和微乳头型与较差无病生存独立相关。
  • 微乳头型与侵袭性复发风险显著相关,需密切随访和肿瘤生育咨询。

核心结论

  • 双侧卵巢囊肿剥除术治疗双侧SBOT可行,肿瘤结局可接受且妊娠率值得肯定。

主要发现

  • 中位随访64个月(范围4-243个月),61例(65%)复发:根治组3例(20%)、UAC组26例(84%)、双侧囊肿剥除组32例(67%)。
  • 多因素分析显示术前CA-125>300 U/mL、保留生育手术和微乳头型分别与不良无病生存独立相关(P=0.001、0.03和0.026)。
  • 49例尝试妊娠者中23例(47%)获得27次妊娠(24次自然妊娠、3次IVF-ET后),获19例活产。
  • UAC与双侧手术的无病生存(P=0.13)和妊娠率(41% vs 50%,P=0.56)无显著差异。

临床怎么用

  • 双侧SBOT技术可行时,可推荐超保守的双侧卵巢囊肿剥除术以保留生育功能。
  • 对微乳头型患者应加强随访和肿瘤生育咨询,警惕侵袭性演变。

局限性

  • 回顾性研究存在固有偏倚,治疗分组非随机且尝试妊娠患者较少可能限制统计效能。
  • 仅41例(43.6%)初次手术接受完整分期,可能低估FIGO分期和卵巢外种植。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What are the oncofertility outcomes of young women (≤40 years old) with bilateral serous borderline ovarian tumors (SBOTs) after fertility-sparing surgery? SUMMARY ANSWER: Fertility preservation with the bilateral ovarian cystectomy procedure is feasible for bilateral SBOTs, with an acceptable oncological outcome and worthwhile pregnancy rates. WHAT IS KNOWN ALREADY: Fertility-sparing approaches are becoming the standard management of young patients with unilateral SBOTs and other borderline histological subtypes. However, there is a paucity of evidence to dictate the best management in bilateral SBOTs. STUDY DESIGN, SIZE, DURATION: This was a retrospective observational study performed at the Peking Union Medical College Hospital in Beijing, China, between January 1999 and January 2019. PARTICIPANTS/MATERIALS, SETTING, METHODS: Ninety-four women (≤40 years old) with pathologically confirmed bilateral SBOTs were included. Following preoperative counseling, patients self-selected into one of three treatment modalities: bilateral ovarian cystectomy (n = 48), unilateral adnexectomy plus contralateral cystectomy (UAC; n = 31), and radical surgery (n = 15). Univariate and multivariate analyses were used to determine the clinical and pathological features associated with disease-free survival and reproductive outcomes. MAIN RESULTS AND THE ROLE OF CHANCE: During the median follow-up of 64 months (range, 4-243 months), 61 patients (65%) developed relapse, including 3 (20%) in the radical group, 26 (84%) in the UAC group and 32 (67%) in the bilateral cystectomy group. In the multivariate analyses, preoperative CA-125>300 U/mL, fertility preservation and micropapillary pattern were independently associated with adverse disease-free survival (P = 0.001, 0.03 and 0.026, respectively). Fourteen patients (15%) experienced invasive recurrence, and three (3%) died of progressive disease. The micropapillary pattern was significantly associated with invasive evolution risk (P = 0.006). Of the 49 patients who attempted to conceive, 23 (47%) achieved 27 pregnancies (24 spontaneous and three after IVF-ET), resulting in 19 live births. There was no significant difference in disease-free survival (P = 0.13) or pregnancy rate (41 vs. 50%, P = 0.56) between the UAC and bilateral procedures. LIMITATIONS, REASONS FOR CAUTION: As a retrospective study conducted in a referral center, inherent biases exist. The nonrandom allocation to treatment groups and relatively small number of patients attempt to conceive might limit the statistical power of our findings. Only 41 patients (43.6%) received complete staging during their initial surgeries, so an underestimation bias in terms of the FIGO stage and extraovarian implants might have occurred. WIDER IMPLICATIONS OF THE FINDINGS: The ultraconservative bilateral ovarian cystectomy procedure should be proposed in bilateral SBOTs when technically feasible. Invasive evolution occurs frequently in these women, and intense follow-up and oncofertility counseling are warranted, especially for those with micropapillary patterns. STUDY FUNDING/COMPETING INTEREST(S): No external funding was used for this study. There are no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Jia SZ, Xiang Y, Yang JJ, et al. Oncofertility outcomes after fertility-sparing treatment of bilateral serous borderline ovarian tumors: results of a large retrospective study. Hum Reprod. 2020. PMID: 32048711. doi:10.1093/humrep/dez307

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。